Physician
Aspirus Riverview Hospital & Clinics, INC.
Aspirus Riverview Hospital & Clinics, INC. was paid $10.85M by Medicaid between Jan 2018 and Dec 2024, across 235 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 14% of everything it billed.
33Billing provider infoASPIRUS RIVERVIEW HOSPITAL & CLINICS, INC.
WISCONSIN RAPIDS, WI 54494
WISCONSIN RAPIDS, WI 54494
33aNPI1295754844assigned 07/18/2006
33bProvider typeRadiation Oncology Physician
28Total paid$10.85M
24GClaims632,314
24DCodes billed235
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Radiation Oncology Physician providers in Wisconsin
Rank by total paid#1 of 6
Median peer was paid$144K
This provider vs. median75×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 88,069 | $1.49M | |
| 2019 | 92,013 | $1.47M | |
| 2020 | 88,203 | $1.25M | |
| 2021 | 85,763 | $1.46M | |
| 2022 | 91,876 | $1.66M | |
| 2023 | 103,558 | $1.83M | |
| 2024incomplete | 82,832 | $1.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 12,859 | 9,732 | $1.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 35,772 | 30,410 | $1.29M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 29,934 | 25,850 | $1.19M |
| 80053 | Comprehensive metabolic panel | 4.9% | 32,407 | 25,013 | $536K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 9,990 | 8,623 | $508K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4.1% | 4,969 | 4,325 | $449K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.9% | 7,914 | 5,395 | $425K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 9,224 | 7,765 | $382K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 4,343 | 3,745 | $256K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.3% | 3,102 | 2,511 | $253K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.2% | 3,677 | 2,423 | $240K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 4,309 | 3,754 | $213K |
223 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 36,555 | $208K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 2,963 | $190K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.7% | 2,615 | $186K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 5,671 | $149K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 3,025 | $128K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 779 | $123K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,325 | $104K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,079 | $98K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,980 | $98K |
| 83880 | <1% | 5,149 | $94K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,732 | $94K |
| 84484 | <1% | 14,357 | $86K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,012 | $83K |
| 87070 | <1% | 3,578 | $79K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,215 | $74K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 13,115 | $73K |
| 81025 | <1% | 4,505 | $72K | |
| 81001 | <1% | 16,332 | $67K | |
| 83605 | <1% | 9,600 | $65K | |
| 80306 | <1% | 4,483 | $64K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,075 | $60K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,046 | $59K |
| 85610 | <1% | 9,640 | $56K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,169 | $49K |
| 87400 | <1% | 3,856 | $49K | |
| 83735 | <1% | 12,247 | $46K | |
| 83690 | <1% | 8,936 | $42K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,159 | $41K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,079 | $40K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 583 | $36K |
| 96367 | <1% | 806 | $34K | |
| 80061 | Lipid panel | <1% | 2,493 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 885 | $32K |
| 87088 | <1% | 2,008 | $28K | |
| 86140 | <1% | 7,228 | $28K | |
| 87040 | <1% | 4,756 | $27K | |
| 82948 | <1% | 4,735 | $24K | |
| 87077 | <1% | 2,395 | $24K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,791 | $24K |
| 45384 | <1% | 125 | $23K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,755 | $23K |
| 84145 | <1% | 1,903 | $23K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 661 | $22K |
| 85730 | <1% | 6,134 | $21K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,044 | $21K |
| 59025 | Fetal non-stress test | <1% | 301 | $21K |
| 86850 | <1% | 1,649 | $20K | |
| 85379 | <1% | 3,185 | $20K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 430 | $19K |
| 84703 | <1% | 2,401 | $17K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 393 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 426 | $16K |
| 82550 | <1% | 4,366 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,341 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,788 | $16K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 321 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 428 | $15K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 333 | $15K |
| 81003 | <1% | 2,469 | $14K | |
| 84702 | <1% | 650 | $14K | |
| 76801 | <1% | 352 | $14K | |
| 82553 | <1% | 3,521 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,510 | $13K |
| 96368 | <1% | 285 | $12K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,089 | $12K |
| 87210 | <1% | 839 | $12K | |
| 84439 | <1% | 1,285 | $12K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 316 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 959 | $10K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 394 | $10K |
| 82728 | <1% | 760 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 223 | $9K |
| 82977 | <1% | 1,480 | $9K | |
| 87807 | <1% | 589 | $9K | |
| 87186 | <1% | 2,063 | $9K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,462 | $9K |
| 85027 | <1% | 2,114 | $9K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 542 | $8K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 176 | $8K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 101 | $8K |
| 86900 | <1% | 1,892 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 216 | $7K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 52 | $6K |
| 93976 | <1% | 173 | $6K | |
| 82805 | <1% | 334 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 201 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,349 | $5K |
| 74018 | <1% | 663 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 12 | $5K |
| 83874 | <1% | 709 | $5K | |
| 12001 | <1% | 76 | $5K | |
| 73630 | <1% | 913 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,528 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 86 | $4K |
| 97597 | <1% | 156 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 564 | $4K |
| 73564 | <1% | 744 | $4K | |
| 86901 | <1% | 1,897 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 71 | $4K |
| 93017 | <1% | 122 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 218 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,002 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,793 | $4K |
| 85652 | <1% | 1,852 | $3K | |
| 80329 | <1% | 645 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,255 | $3K |
| 85007 | <1% | 1,089 | $3K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 165 | $3K |
| 36591 | <1% | 535 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 70 | $2K |
| 73030 | <1% | 408 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 197 | $2K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 73 | $2K |
| 72110 | <1% | 462 | $2K | |
| 73610 | <1% | 557 | $2K | |
| 73130 | <1% | 444 | $2K | |
| 87634 | <1% | 40 | $2K | |
| 82274 | <1% | 70 | $2K | |
| 93971 | <1% | 58 | $2K | |
| 73110 | <1% | 124 | $2K | |
| 82950 | <1% | 76 | $2K | |
| 83550 | <1% | 314 | $2K | |
| 83540 | <1% | 322 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 60 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 825 | $1K |
| 82803 | <1% | 81 | $1K | |
| 86803 | <1% | 57 | $1K | |
| 43248 | <1% | 13 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 55 | $906.80 |
| 87340 | <1% | 87 | $896.65 | |
| 82565 | <1% | 89 | $869.93 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 43 | $771.24 |
| 87205 | <1% | 270 | $762.97 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,121 | $695.87 |
| 80320 | <1% | 1,252 | $682.21 | |
| 84153 | <1% | 68 | $674.13 | |
| 90715 | <1% | 128 | $618.37 | |
| 80076 | <1% | 77 | $596.11 | |
| 99223 | Prolong inpt eval add15 m | <1% | 16 | $568.88 |
| 74019 | <1% | 187 | $568.12 | |
| 83615 | <1% | 143 | $559.84 | |
| 82105 | <1% | 13 | $531.66 | |
| 99152 | <1% | 779 | $404.92 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 58 | $312.33 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $277.65 |
| 84550 | <1% | 86 | $239.62 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 131 | $220.07 |
| 94060 | <1% | 13 | $171.52 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 516 | $171.09 |
| 80050 | General health panel | <1% | 64 | $141.40 |
| 84481 | <1% | 13 | $137.95 | |
| 97162 | <1% | 41 | $135.52 | |
| 87075 | <1% | 18 | $108.38 | |
| 86308 | <1% | 28 | $101.92 | |
| 96376 | <1% | 2,183 | $100.10 | |
| 99157 | <1% | 161 | $98.27 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $97.53 |
| 94729 | <1% | 13 | $95.80 | |
| 85018 | <1% | 57 | $93.76 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,747 | $92.44 |
| 73502 | <1% | 44 | $91.26 | |
| 82607 | <1% | 16 | $84.57 | |
| 99156 | <1% | 165 | $71.81 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,005 | $59.56 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,924 | $54.91 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 90 | $54.68 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,380 | $51.43 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,652 | $51.19 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,983 | $49.05 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,520 | $47.98 |
| Q3014 | Telehealth originating site facility fee | <1% | 14 | $47.60 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,782 | $45.67 |
| 84100 | <1% | 18 | $44.10 | |
| 36000 | <1% | 467 | $32.72 | |
| 82570 | <1% | 18 | $32.69 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,572 | $24.41 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,778 | $21.87 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,778 | $21.51 |
| 88342 | <1% | 118 | $17.57 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,494 | $14.88 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,773 | $11.65 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 765 | $9.80 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 874 | $8.68 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 121 | $8.65 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 518 | $8.54 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,866 | $8.06 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,568 | $7.33 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,166 | $5.58 |
| G0008 | Administration of influenza virus vaccine | <1% | 15 | $5.04 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 473 | $3.15 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 298 | $2.84 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 919 | $2.71 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 517 | $2.60 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 899 | $2.26 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 44 | $1.05 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,425 | $0.67 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,176 | $0.44 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 20 | $0.29 |
| A9270 | Non-covered item or service | <1% | 20,576 | $0.23 |
| 82043 | <1% | 13 | $0.14 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,122 | $0.04 |
| J3490 | Unclassified drugs | 0% | 207 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 51 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 337 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 607 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 96 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 40 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 103 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 675 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 285 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 657 | $0.00 |
| 88312 | 0% | 87 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 173 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 24 | $0.00 |
| A4565 | Slings | 0% | 57 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 58 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 97 | $0.00 |
| 51702 | 0% | 15 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 29 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 32 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.